Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, November 7, 2023
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
[ Tue, Nov 07th 2023
] - WOPRAI
Joseph Stringer Maintained (STOK) at Strong Buy with Decreased Target to $14 on, Nov 7th, 2023
Joseph Stringer of Needham, Maintained "Stoke Therapeutics, Inc." (STOK) at Strong Buy with Decreased Target from $25 to $14 on, Nov 7th, 2023.
Joseph has made no other calls on STOK in the last 4 months.
There are 3 other peers that have a rating on STOK. Out of the 3 peers that are also analyzing STOK, 0 agree with Joseph's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Joseph
- Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $35 on, Tuesday, August 8th, 2023
- Charles Duncan of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $14 on, Tuesday, August 8th, 2023
- Judah Frommer of "Credit Suisse" Reiterated at Buy and Held Target at $23 on, Tuesday, August 8th, 2023
